(Q44543810)

4 December 2017

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution (English)

1 reference

4 December 2017

0 references

1 reference

ChEBI release 2020-05-28

6

Eric Q Wu

1 reference

4 December 2017

Gregory S Sawicki

1

1 reference

4 December 2017

James E Signorovitch

2

1 reference

4 December 2017

Jie Zhang

3

1 reference

4 December 2017

Dominick Latremouille-Viau

4

1 reference

4 December 2017

Markus von Wartburg

5

1 reference

4 December 2017

Lizheng Shi

7

1 reference

4 December 2017

3 August 2011

1 reference

4 December 2017

Pediatric Pulmonology

1 reference

4 December 2017

47

1 reference

4 December 2017

1

1 reference

4 December 2017

44-52

1 reference

Predictive 5-year survivorship model of cystic fibrosis

4 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

A prognostic model for the prediction of survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Models for longitudinal data: a generalized estimating equation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Adherence to treatment in children and adolescent patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Case-mix adjustment for evaluation of mortality in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Gender gap in cystic fibrosis mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Prevalence and impact of depression in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Factors influencing outcomes in cystic fibrosis: a center-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

21 January 2018

Identifiers

DOI

10.1002/PPUL.21521

1 reference

4 December 2017

1 reference